Watson acquires Novartis's pain products. (Business in Brief).(Watson Pharmaceuticals Inc. is acquiring the US rights to the Fioricet and Fiorinal product lines)(Brief Article)

Chemical Market Reporter, January, 2003

Watson Pharmaceuticals Inc. has agreed to acquire the US rights from Novartis Pharmaceuticals Corp. of the Fioricet and Fiorinal product lines, indicated for treatment of tension headaches, for $178 million. Novartis will manufacture the products for Watson for a transitional period.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here